A team of researchers from Niigata University and the University of Tokyo will begin clinical tests this year of medicines to treat people with familial Alzheimer's disease.
The tests will aim to remove abnormal proteins inside the brain that are believed to cause Alzheimer's. The subjects will be people from families that have a tendency to develop hereditary dementia, which can present symptoms while the patient is still young.
The plan was examined by the two universities' review boards for clinical tests in late February. Niigata University has given its approval, while the University of Tokyo has approved the plan with the condition that relevant documents will be revised.
